During the epidemic, endorphins showed excellent analgesic effects in critically ill patients. Alpha-endorphin not only showed excellent analgesic effects, but also made patients feel relaxed and happy.
Kechuang Bio's large donation during the epidemic and Endorphin's excellent performance in Jiangcheng have allowed Endorphin to develop rapidly in the domestic market.
It was precisely because of the good performance of the epidemic that when the epidemic situation of Americen surged, the FDA accelerated the approval of Endorphin. After Endorphin was approved, it was put on sale in Americen.
"It's not that I don't supply, it's that our production capacity is really limited. Our annual production capacity is only 8,000L. Domestic supply needs to be stable, and Americen also needs to supply. We have no surplus to provide to the Lion City." Cheng Gang explained road.
"Representatives from Europa's representative office in Shenhai came to Kechuang Biotech two days ago. They hope that we can provide a batch of drugs to Europa, saying that they can buy them at twice the price."
"We still refuse. Insufficient production capacity is the biggest limitation to our current development."
Since the number of confirmed cases in the Lion City exceeded 100 at the end of February, now in May, the daily number of confirmed cases in the Lion City has exceeded double digits.
The epidemic may break through the Lion City's medical defense line at any time. For endorphins, which perform well during the epidemic, the Lion City is eager to purchase a batch of drugs.
Endorphins are now equivalent to a monopoly, and only Kechuang Biotechnology can provide them.
However, since the analgesic market is not a monopoly, and there are a series of drugs such as morphine and fentanyl that compete with it, Kechuang Biotech cannot be sued in the name of monopoly.
Ho Ching, head of Temasek’s science and technology innovation project, said:
"As shareholders of Kechuang Biotechnology, it is normal for us to get part of the production capacity, right? And if the production capacity is insufficient, we will expand production. Now that the global epidemic is developing rapidly, the market for endorphins is very broad."
“Our valuation at that time was that endorphins could account for 40% of the global analgesic market share. Now it seems that it is entirely possible to account for 60 to 70% of the market share. "
"Now that the market prospects are so bright, we should go and capture the market."
"Don't say so much, but at least guarantee that I will be given 5% of the production capacity, my shareholding will be 5%, and I will be given 5% of the production capacity."
Temasek is the sovereign fund of the Lion City, which represents the will of the country to a certain extent. When the epidemic breaks out on a global scale, medicines are more precious than gold.
“We in Lion City are willing to pay three times the price for endorphins.”
In the black market, endorphins are hard currency with a price but no market. Compared with the ex-factory price of Kechuang Biotech, the black market price is at least three times higher.
Because this thing is in the late stage of COVID-19, a dose can have a cardiotonic effect. It is possible to survive after taking a shot of endorphins.
Cheng Gang: "I also want to expand production capacity. The problem is that it takes time to expand production capacity. The industrial production of endorphins has high requirements on operators. Our current operators have been trained for half a year before they gradually take up the job."
“The yield rate was less than 80% in the early stage after they took up the job, and it is only now slowly improving.”
"The fully automated production line for endorphins is still in the bidding stage, and we haven't decided which manufacturer will do it yet."
"Currently, Kechuang Biotech still has US$5 billion in cash on its books. We are not short of money now. Expanding production capacity is not just a matter of money. We need to respect the objective laws of the development of things."
"Due to the epidemic, in order to expand production capacity, the recently recruited masters and even PhDs have begun to work on the production line."
“As for the five percent share given to the Lion City, Kechuang Biotech’s production capacity for the next eight months has been locked in advance by Americen and Chinese companies. We have already signed a contract and cannot free up production for the Lion City. "
"Don't talk about you today. Even if Director Zheng asks me, I won't be able to provide production to Lion City."
He Jing asked: "Can Kechuang Biotech authorize biopharmaceutical companies in the Lion City to produce endorphins?"
Cheng Gang: "Authorization is possible, but there are a few questions. How to charge the authorization fee?"
“If we authorize biopharmaceutical companies in the Lion City, do we also need to authorize other international pharmaceutical companies?”
"In addition, it will take at least half a year from authorization to when you start production. How will the epidemic develop in half a year?"
"Without the support from Kechuang Biotech's technical staff, it would have taken more than half a year for you to officially produce. But we can't allocate manpower to help you build the factory now, and it's too late for us to expand our production capacity ourselves."
"And whether to license the endorphin synthesis pathway to other pharmaceutical companies needs to be decided by Director Zheng. I haven't seen Director Zheng for at least three months."
"Only Mr. Li from Ke Chuang Biotech can meet with Director Zheng once a month to report on her work. The next time she will see Director Zheng will be three days later. I can ask her to ask Director Zheng for his opinion."
"I cannot make decisions on such a critical issue now."
“There are many biopharmaceutical companies in the Lion City, and we can let them first produce a batch of endorphins through laboratory methods for later use.”
"Or you can discuss with Maxson and let them free up some of their production capacity for you."
McKesson is a pharmaceutical sales company that has locked in part of its endorphin production capacity in advance.
He Jing knew that his pressure had failed: "I hope to get a reply from Director Zheng as soon as possible. Also, please ask if Director Zheng can optimize the industrial production process."
"Expand production capacity ahead of schedule."
The current situation of Kechuang Biotechnology is that it is not short of money. It has money on its books that cannot be spent, and its products are still in short supply.
There have been voices in the domestic securities market that science and technology biotech should be listed on the science and technology innovation board. The listing of science and technology innovation and biotechnology on the science and technology innovation board must be the leader of the science and technology innovation board.
Stock investors even jokingly said that the name of Ke Chuang Bio was born to be prepared for the Science and Technology Innovation Board. The reason why there has been little improvement since the establishment of the Science and Technology Innovation Board is because Ke Chuang Bio has not been listed on the Science and Technology Innovation Board.
So much so that when the leaders of the Securities Regulatory Bureau came to Suzhou, they inspected Kechuang Biotech and asked when Kechuang Biotech planned to go public and whether it would consider listing on the Science and Technology Innovation Board.
Domestic Internet companies generally list on Nasdaq or Hong Kong stocks, and domestic pharmaceutical companies generally choose domestic or Hong Kong stocks to list.
Because there is no shortage of excellent pharmaceutical companies in Americen, domestic pharmaceutical companies cannot get a good valuation if they go public with Americen.
The current market situation is that the outside world is looking forward to when Kechuang Bio will be listed. Ke Chuang Bio is not in a hurry, they are not short of money at all.
Generally, companies go public because they need to raise funds to enable the company to develop better, which is a necessary stage in development.
Even BOCOM International is not in a hurry to list Kechuang Biotechnology, let alone several other investment institutions.
They hope that Kechuang Biotech will develop for a while and have a better valuation before going public.
It is best to go public in 2021, because due to the impact of the epidemic in 2020, Kechuang Biotech's 2020 financial report will definitely be particularly good-looking.
